-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to incomplete statistics, as of February 18, more than 200 local pharmaceutical companies have released their 2021 performance forecasts
.
Recently, another pharmaceutical company disclosed its 2021 performance forecast
.
The performance forecast released by GenScript Biotechnology shows that in fiscal 2021, the adjusted net profit of the group business (non-cell therapy business) excluding the subsidiary Legend Biotechnology was about US$48 million to US$51.
6 million, compared with the same period in 2020.
About US$42.
5 million increased by 12.
9% to 21.
4% year-on-year
.
According to public information, GenScript Biotechnology is a provider of life science research and application services and products.
The company has established four major platforms, including the Trusted Research Machine (CRO) platform, the Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) platform, Industrial synthetic product platform and comprehensive global cell therapy platform
.
The company's overall profitability in the second half of 2021 was outstanding.
Its non-cell therapy business adjusted net profit of approximately US$21.
8 million to US$25.
4 million, a year-on-year increase of 19.
8% to 39.
6% compared with approximately US$18.
2 million in the same period in 2020
.
During the reporting period, the improvement of the company's profitability mainly benefited from three aspects: first, the revenue and profitability of the company's life science business continued to maintain healthy growth; Profitability continues to improve; thirdly, the profitability improvement plan adopted by the subsidiary Bestijie in fiscal year 2021 has produced positive results
.
According to the announcement, its subsidiary Legend Bio is expected to record an adjusted loss of approximately US$335.
8 million to US$364.
7 million in the field of cell therapy
.
During the reporting period, the sales and marketing expenses of Legend Bio increased, mainly due to the expenses incurred in the preparation of the commercialization activities of Sidaki Orenza
.
Multiple myeloma is one of the three major malignant tumors of the blood system, which occurs in the elderly over 60 years old with low immune function
.
The disease is currently incurable and prone to recurrence
.
If not treated in time, it will lead to bone marrow failure, bone destruction, hypercalcemia, anemia, infection, renal failure and other symptoms, which will seriously affect the long-term survival of patients
.
According to statistics released by the International Myeloma Foundation, there are approximately 750,000 patients with multiple myeloma worldwide
.
It is understood that Cidaki Orenza is a BCMA-targeted CAR-T product developed by Legend Bio.
The therapy contains a 4-1BB co-stimulatory domain and two BCMA-targeted single-domain antibodies, which are designed to increase its targeting to cancer cells.
Comprehensive capabilities for the treatment of adults with relapsed/refractory multiple myeloma (MM)
.
In December 2017, Legend Bio entered into a global license and collaboration agreement with Janssen, a Johnson & Johnson subsidiary, to develop and commercialize Cedarquiorenza
.
In 2018, the therapy obtained the first CAR-T clinical trial application (IND) approval from the State Food and Drug Administration of China and IND approval from the US FDA.
therapy approval
.
At present, the legendary creature is in full swing to prepare for the commercialization of Sidaki Orenza
.
Legend Bio has submitted a rolling submission of the Biologics License Application (BLA) to the U.
S.
FDA in December 2020, and the FDA is currently making a decision on whether to approve the Prescription Drug User Fee Act (PDUFA) target date for the listing of Cedarquiorenza.
as of February 28, 2022
.
With the launch of this breakthrough CAR-T therapy product, it is expected to bring more treatment options to patients with multiple myeloma, and at the same time have a positive impact on the company's performance
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Recently, another pharmaceutical company disclosed its 2021 performance forecast
.
The performance forecast released by GenScript Biotechnology shows that in fiscal 2021, the adjusted net profit of the group business (non-cell therapy business) excluding the subsidiary Legend Biotechnology was about US$48 million to US$51.
6 million, compared with the same period in 2020.
About US$42.
5 million increased by 12.
9% to 21.
4% year-on-year
.
According to public information, GenScript Biotechnology is a provider of life science research and application services and products.
The company has established four major platforms, including the Trusted Research Machine (CRO) platform, the Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) platform, Industrial synthetic product platform and comprehensive global cell therapy platform
.
The company's overall profitability in the second half of 2021 was outstanding.
Its non-cell therapy business adjusted net profit of approximately US$21.
8 million to US$25.
4 million, a year-on-year increase of 19.
8% to 39.
6% compared with approximately US$18.
2 million in the same period in 2020
.
During the reporting period, the improvement of the company's profitability mainly benefited from three aspects: first, the revenue and profitability of the company's life science business continued to maintain healthy growth; Profitability continues to improve; thirdly, the profitability improvement plan adopted by the subsidiary Bestijie in fiscal year 2021 has produced positive results
.
According to the announcement, its subsidiary Legend Bio is expected to record an adjusted loss of approximately US$335.
8 million to US$364.
7 million in the field of cell therapy
.
During the reporting period, the sales and marketing expenses of Legend Bio increased, mainly due to the expenses incurred in the preparation of the commercialization activities of Sidaki Orenza
.
Multiple myeloma is one of the three major malignant tumors of the blood system, which occurs in the elderly over 60 years old with low immune function
.
The disease is currently incurable and prone to recurrence
.
If not treated in time, it will lead to bone marrow failure, bone destruction, hypercalcemia, anemia, infection, renal failure and other symptoms, which will seriously affect the long-term survival of patients
.
According to statistics released by the International Myeloma Foundation, there are approximately 750,000 patients with multiple myeloma worldwide
.
It is understood that Cidaki Orenza is a BCMA-targeted CAR-T product developed by Legend Bio.
The therapy contains a 4-1BB co-stimulatory domain and two BCMA-targeted single-domain antibodies, which are designed to increase its targeting to cancer cells.
Comprehensive capabilities for the treatment of adults with relapsed/refractory multiple myeloma (MM)
.
In December 2017, Legend Bio entered into a global license and collaboration agreement with Janssen, a Johnson & Johnson subsidiary, to develop and commercialize Cedarquiorenza
.
In 2018, the therapy obtained the first CAR-T clinical trial application (IND) approval from the State Food and Drug Administration of China and IND approval from the US FDA.
therapy approval
.
At present, the legendary creature is in full swing to prepare for the commercialization of Sidaki Orenza
.
Legend Bio has submitted a rolling submission of the Biologics License Application (BLA) to the U.
S.
FDA in December 2020, and the FDA is currently making a decision on whether to approve the Prescription Drug User Fee Act (PDUFA) target date for the listing of Cedarquiorenza.
as of February 28, 2022
.
With the launch of this breakthrough CAR-T therapy product, it is expected to bring more treatment options to patients with multiple myeloma, and at the same time have a positive impact on the company's performance
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
